Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ: CNSP )

0.1088 -0.0002 (-0.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Management, Dr. Samuel Goldlust Participate in Virtual Investor KOL Connect Segment
Via Investor Brand Network
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
Via ACCESSWIRE
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
Via ACCESSWIRE
Jimmy Carter Survival Thanks to Novel Cancer Immunotherapy Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum
Via Investor Brand Network
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
Via ACCESSWIRE
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Via ACCESSWIRE
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
Via ACCESSWIRE
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
WHO Review Says No Link Between Mobile Phones, Brain-Cancer Development
Via Investor Brand Network
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Slated to Present at H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Latest BioMedWire Podcast Episode
Via Investor Brand Network
What's Going On With CNS Pharmaceuticals Stock Tuesday?
CNS Pharmaceuticals entered into a exclusive license agreement with Cortice Biosciences. 
Via Benzinga
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Upcoming Virtual Investor CEO Connect Segment
Via Investor Brand Network
Scientists Find Way to Boost Natural Killer Cells Targeting Pediatric Brain Cancer
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Publishes Q2 2024 Results
Via Investor Brand Network
Exposures Product Safety
CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q2 2024
CNS Pharmaceuticals just reported results for the second quarter of 2024. 
Via InvestorPlace
Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Study Uncovers How Brain Tumors Evolve During Treatment
Via Investor Brand Network
Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Microsoft Office Outage: Microsoft Investigates Applications, Services Issue
A Microsoft Office outage has workers annoyed as its causing problems with them being able to use the company's services. 
Via InvestorPlace
SOUN Stock Alert: SoundHound Expands AI Rollout with Stellantis
SoundHound AI stock is up on Tuesday as SOUN investors react well to the company's voice assistant coming to Stellantis vehicles. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?
CNS Pharmaceuticals stock is falling hard on Tuesday as CNSP investors aren't happy about its latest license expansion. 
Via InvestorPlace
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Inks Exclusive License in ‘Transformational’ Step to Treating GBM
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Dow Jumps 200 Points; Pfizer Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.